Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 4th TCR-based Therapies for Solid Tumors Summit in Boston from April 3 to 5, 2023.
On April 4, 2023, Prof. Schendel will first join the Industry Leaders’ Fireside Chat ”What’s Next for T-Cell Receptor Therapies?”, followed by her presentation (see details below).
TCR-based Therapies for Solid Tumors Summit
https://tcr-therapies-summit.com/
Date: April 4, 2023
Presenter: Prof. Dr. Dolores Schendel, CSO
Presentation: Case Study Spotlight: Introducing Innovations at Each Step of TCR-T Therapy Development
Medigene’s management team will be available for one-on-one meetings at the event. Please contact Sandya von der Weid of LifeSci Advisors at svonderweid@lifesciadvisors.com to schedule a meeting.
--- end of press release ---
About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, t cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
